Delair Gardi
Interventional Cardiology · Detroit, MINPI 1205874302
Payments from drug & device makers
Across 1,018 payments — averaging $61.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lexicon Pharmaceuticals, Inc.$25K
- AstraZeneca$10K
- Avinger Inc.$3K
- Esperion Therapeutics, Inc.$3K
- Edwards Lifesciences$2K
- Inari Medical, Inc.$2K
- plus $17K from 51 others
What the payments were for
- Speaking & faculty fees$33,99554%
- Travel & lodging$8,10713%
- Food & beverage$20,53733%
- Education$1430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inpefa$24,741
- FARXIGA$8,731
- NEXLIZET$2,946
- NEXLETOL$2,946
- PANTHERIS$2,918
- FLOWTRIEVER CATHETER, S$2,128
- CT THROMBECTOMY SYSTEM KIT$2,128
- PASCAL$1,096
- Edwards SAPIEN 3 Transcatheter Heart Valve$867
- LUX-Dx Insertable Cardiac Monitor$264
- Alto Abdominal Stent Graft System$196
- ONYX FRONTIER$154
- COBALT DR MRI SURESCAN$151
- EMBLEM MRI S-ICD$140
- Claria MRI$136
- HawkOne$125
- GENERAL ANGIOPLASTY$123
- Repatha$121
- Micra$111
- Assure WCD$110
How this compares
$62,782 in reported general payments places this provider in the 70th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 578 | $546,026 |
| EntrestoSacubitril/Valsartan | 441 | $493,779 |
| XareltoRivaroxaban | 413 | $381,369 |
| FarxigaDapagliflozin Propanediol | 156 | $153,237 |
| JardianceEmpagliflozin | 139 | $144,337 |
| BrilintaTicagrelor | 164 | $121,864 |
| Repatha SureclickEvolocumab | 54 | $52,260 |
| Metoprolol Succinate | 1,925 | $23,372 |
| VerquvoVericiguat | 25 | $18,362 |
| Ranolazine ErRanolazine | 235 | $17,739 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $15,258 |
| MultaqDronedarone Hcl | 19 | $15,018 |
| Nitroglycerin | 639 | $11,965 |
| ClopidogrelClopidogrel Bisulfate | 869 | $11,883 |
| Atorvastatin Calcium | 1,158 | $11,824 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $848 | $546,026578 claims |
| NovartisEntresto | $1,962 | $493,779441 claims |
| Johnson & JohnsonXarelto | $1,534 | $381,369413 claims |
| AstraZenecaFarxiga, Brilinta | $9,653 | $275,101320 claims |
| Boehringer IngelheimJardiance | $675 | $144,337139 claims |
| MerckVerquvo | $595 | $18,36225 claims |
| Esperion Therapeutics, Inc.Nexlizet | $3,153 | $15,25813 claims |
| Sanofi-aventis U.S. LLCMultaq | $88 | $15,01819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Detroit
- Amir KakiDetroit$2.3M
- Khaldoon AlaswadDetroit$1.1M
- Tamam MohamadDetroit$960K
- Mir BasirDetroit$771K
- M Chadi AlraiesDetroit$245K
- Brittany FullerDetroit$129K
- Zaher HakimDetroit$92K
- William MerhiGrand Rapids$2M
- Shukri DavidSouthfield$1.6M
- Qaiser ShafiqSouthgate$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.